Early Versus Ultra Early Surgical Treatment of Ruptured Intracranial Aneurysms
Launched by REVAZ DZHINDZHIKHADZE · Jun 9, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the best timing for surgery in adults who have experienced a ruptured brain aneurysm, which can cause bleeding in the brain (a condition known as aneurysmal subarachnoid hemorrhage). The researchers want to find out if performing surgery within 24 hours of the rupture (called ultra-early intervention) leads to better survival rates and fewer complications compared to surgery done a bit later, between 24 and 72 hours after the rupture. By comparing these two timing options, they hope to understand which approach is safer and more effective for patients.
To participate in this trial, individuals must have had a ruptured brain aneurysm and be eligible for surgery. They will be randomly assigned to one of the two surgery timing groups. Throughout the study, participants will visit the clinic for follow-up appointments at 1 month, 3 months, 6 months, and 12 months after their surgery. They will also keep a diary to track their symptoms, how well they are functioning, and any complications they may experience after the surgery. This trial is currently not recruiting participants, but it aims to help improve treatment options for those affected by this serious condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • aneurysmal subarachnoid hemorrhage
- • patient eligible for surgical clipping
- • patients with informed consent for inclusion into the study
- Exclusion Criteria:
- • patients admitted and treated \>72 h after subarachnoid hemorrhage onset
- • patients with severe comorbidities
- • patients with multiple aneurysms
About Revaz Dzhindzhikhadze
Revaz Dzhindzhikhadze is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on developing effective therapeutic solutions, the organization collaborates with leading researchers and healthcare professionals to design, implement, and oversee clinical trials across various therapeutic areas. Revaz Dzhindzhikhadze emphasizes rigorous adherence to regulatory standards and ethical practices, ensuring the safety and well-being of participants while striving to bring groundbreaking treatments to market. Their mission is to contribute to the improvement of patient outcomes through high-quality, evidence-based research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported